Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Immune Checkpoint Inhibitors (ICIs) Therapy (to improve) & Drugs/Treatments

Navigation

Contents

This means reducing side effects and/or improving effectiveness.

Reducing side effects

Improving effectiveness

see also:
Adverse Events / Safety & Anti-CTLA-4 / CTLA-4
Adverse Events / Safety & Anti-PD-1 antibodies / PD-1 inhibitors
Adverse Events / Safety & Anti-PD-L1 antibodies / PD-L1 inhibitors
[Adverse Events / Safety & Immune Checkpoint Inhibitors (ICIs)]

References (Sources)

Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO)
Tan 2019a ASCO #TPS2664
Fecal microbiota transplantation improves anti-PD-1 inhibitor efﬁcacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
Kim et al. 2024a Cell Host & Microbe 32(8): 1380-1393
Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events
Desilets & Elkrief 2023 Current Opinion in Oncology 35(4): 248-253
Review
How microbiota improve immunotherapy
Ansaldo & Belkaid 2021 Science 373: 966-967
Intestinal microbiota predicts lung cancer pts at risk of immune-related diarrhea
Liu et al. 2019b
The heightened importance of the microbiome in cancer immunotherapy
Villemin et al. 2023 Trends in Immunology 44(1): 44
Review

AI Chat

11/5/2026

Chat with our artificial intelligence: